CFM
THRD

Catalyst Funds Management’s Third Harmonic Bio THRD Stock Holding History

Catalyst Funds Management’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,600
Closed -$112K – 1599
2024
Q2 		$112K Hold
8,600
– – 0.03% 268
2024
Q1 		$81.2K Buy
+8,600
New +$83.6K 0.02% 449

Other funds holding THRD

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Catalyst Funds Management's THRD Position: Q3 2024 in Review

Catalyst Funds Management sold out of Third Harmonic Bio (THRD) in Q3 2024, closing a stake of 8,600 shares — an estimated $112K sold.

Catalyst Funds Management first reported a position in THRD in Q1 2024 and held it in 2 quarters. The position peaked at $112K in Q2 2024. 84 funds tracked by Wall St. Rank hold THRD as of Q3 2024.

  • Catalyst Funds Management reported no remaining Third Harmonic Bio position as of Q3 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 8,600 Third Harmonic Bio shares in Q3 2024, an estimated $112K.
  • Catalyst Funds Management first reported a position in Third Harmonic Bio in Q1 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Third Harmonic Bio position peaked at $112K in Q2 2024.
  • 84 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q3 2024.

Based on Catalyst Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.